Alzheimer’s Disease – Special Topics – Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS covering the drug in line with its label and broadening reimbursement of PET scans used to establish diagnoses and determine treatment eligibility, Leqembi is poised to capitalize on the unfulfilled potential for an AD DMT. However, logistic hurdles on the path to diagnosis and treatment initiation must be overcome to unlock the full potential of a DMT in the AD market. This survey-based report assesses U.S. caregivers’ experiences with their patient’s path to diagnosis of AD, unspecified dementia, or unspecified MCI. It also explores caregivers’ awareness of, familiarity with, and perceptions of Leqembi, including their willingness to seek treatment or drive further diagnostic clarity. With additional DMTs expected to enter the market in 2024, the analysis will also shed light on the drivers and constraints influencing the use of Leqembi and identify opportunities for current and future developers to support DMT uptake.
Questions answered
- What are the drivers of / obstacles to diagnosis of AD or related disorders according to caregivers?
- What is the level of awareness of and familiarity with Leqembi among U.S. caregivers in the first year after launch?
- How do U.S. caregivers perceive Leqembi as a treatment for AD, and how willing are they and their patients to seek treatment?
- Is the approval of Leqembi driving caregivers of unspecified dementia or MCI patients to seek a more granular diagnosis?
Product description
Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help developers in shaping their market strategies, identifying potential areas for differentiation, and caregivers’ receptivity.
Meher Baba Kumar Nakka, M.S.(Pharm.), is a senior healthcare research & data analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this capacity, he works on a range of neurological indications, such as pain and migraine, and neurodegenerative disorders, such as Alzheimer’s disease. He holds a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad and a master’s degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research in Mohali.
John Crowley, Ph.D., is the principal director of the Infectious, Niche, & Rare Diseases team at DRG, part of Clarivate. Prior to his current role, he was a director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. Dr. Crowley holds a Ph.D. from the University of Massachusetts Medical School and a bachelor’s degree from Worcester Polytechnic Institute.